Exane Derivatives Tricida, Inc. Transaction History

Exane Derivatives

  • $157 Million
  • Q2 2022

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 27, 2021
SELL
$4.37 - $9.46 $22,177 - $48,009
-5,075 Closed
0 $0
Q3 2020

Oct 08, 2020
BUY
$8.56 - $26.93 $43,442 - $136,669
5,075 New
5,075 $45,000
Q3 2020

Oct 06, 2020
SELL
$8.56 - $26.93 $28,932 - $91,023
-3,380 Closed
0 $0
Q1 2020

Apr 17, 2020
BUY
$18.43 - $38.04 $62,293 - $128,575
3,380 New
3,380 $74,000

Others Institutions Holding TCDA

# of Institutions
4
Shares Held
30K
Call Options Held
124K
Put Options Held
46.5K
View Full List

About Tricida, Inc.

TCDA Quotes by TradingView
  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email